<DOC>
	<DOCNO>NCT01379807</DOCNO>
	<brief_summary>The clinical hypothesis study addition Panitumumab first line treatment combination docetaxel plus cisplatin provide benefit patient advance gastric gastroesophageal junction adenocarcinoma .</brief_summary>
	<brief_title>Efficacy Safety Panitumumab Combined With Docetaxel Cisplatin First-line Treatment Advanced Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent Inclusion : Age ≥ 18 year Histologically cytologically confirm adenocarcinoma stomach gastroesophageal junction advance unresectable metastatic disease . Measurable disease per revise RECIST ( Response Evaluation Criteria Solid Tumor ) Guidelines ECOG performance score 0 2 Within seven day prior initiate study treatment : Haematology : Neutrophils ≥ 1.5x109 , Platelets ≥ 100x10/ L , Hemoglobin ≥ 9g/dL . Hepatic function : Total bilirubin ≤ 1.5 time upper normal limit ( UNL ) , ASAT ≤ 2.5xUNL absence liver metastasis , ≤5xUNL presence liver metastasis , ALAT ≤ 2.5xUNL absence liver metastasis , ≤5xUNL presence liver metastasis . Renal function : creatinine clearance ≥50 mL/min . Metabolic Function : Magnesium ≥ low limit normal , Calcium ≥ low limit normal . Prior chemotherapy anticancer therapy advance unresectable metastatic disease ( 1st line ) Prior antiEGFR antibody therapy ( e.g . cetuximab ) treatment small molecule EGFR inhibitor ( e.g . erlotinib ) . HER2positive tumor ( centrally assess ) Past current history ( within last 5 year prior treatment start ) malignancies except gastric cancer ( Patients curatively treat basal squamous cell carcinoma skin situ carcinoma cervix eligible ) Current prior history central nervous system metastases Evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatmentrelated complication Treatment investigational agent , participation another clinical trial within 30 day prior enter study Known hypersensitivity study drug Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrollment History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Subject pregnant breast feeding , plan become pregnant within 6 month end treatment . Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>